EOS to develop own SAR microsatellite constellation

0

Noosphere Gambles’ space portfolio company EOS Data Analytics (EOS) has revealed plans to make its own radar microsatellite constellation.

Under the project, which is called EOS SAR, the plc will build its own synthetic aperture radar (SAR) sensors for constellations, commissioning high revisit time.

EOS is currently developing a low-cost high-performance SAR payload proper for small satellites.

EOS SAR microsatellites will be designed with the ability to act in stripmap spotlight and interferometric modes to support several applications.

Noosphere Hazards managing partner and EOS CEO Max Polyakov said: “EOS learned that the remote reasoning market has strong demand for high-resolution high-quality SAR data, but low supply of such facts.

“The choice of SAR technology is driven by the need to image Earth’s surface at the end of ones tether with dense cloud cover, in any season and all weather. It is critical for users to own access to uninterrupted, persistent situational awareness.”

The SAR payload will special attraction light-weight deployable reflector antennas with high resolution down to 25cm.

The launch year for the before satellite is expected to be 2022 while commercial constellation operations at ones desire commence in 2023.

The company is also planning to deploy dual-frequency operation in X and S packs on a single satellite.

Polyakov added: “EOS is strategically leveraging deep skill and diverse capabilities within Noosphere Ventures portfolio including radar electronics, deployable antennas, driving systems, batteries and data analytics in order to create a SAR payload technology, which fires unsurpassable performance at an unbeatable price.

“At the same time, we are open to help and are currently looking for bus providers and a constellation owner to deploy and monetise the constellation. The constellation desire be part of a fully US owned and operated commercial remote sensing initiative.”

Free WhitepaperSix essential ways to improve your pharmaceutical importance system

Enter your details here to receive your release whitepaper.

Pharmaceutical whitepaper

Close survey

Close

Leave a Reply

Your email address will not be published. Required fields are marked *